Document:

Exhibit

    

Back to Form 8-K
Exhibit 10.1
WELLCARE HEALTH PLANS, INC.
EXECUTIVE SEVERANCE PLAN

		
	1.
	Purpose of the Plan

The Board believes that it is in the best interests of the Company to encourage the continued employment and dedication of certain officers by providing economic security to such individuals in the event of certain terminations of employment, and the Plan has been established for this purpose.  The Plan is intended to be a “welfare plan” under ERISA providing benefits to a select group of management or highly compensated employees as described in DOL Regulation section 2520.104-24.  The Plan is separate from the WellCare Health Plans, Inc. Severance Plan, as amended from time to time.  Capitalized terms used in the Plan are defined in Section 10, except as otherwise specified.
		
	2.
	Effective Date

The Plan, as amended and restated effective September 28, 2017, shall be effective only with respect to a termination of employment covered by the Plan that occurs on or after September 28, 2017 (the “Effective Date”).
		
	3.
	Administration

(a)    The Committee shall act as the plan administrator and the “named fiduciary” of the Plan for purposes of ERISA.  Before a Change in Control, the Committee has sole and absolute discretion and authority to administer the Plan, including the sole and absolute discretion and authority to:
(i)    adopt such rules as it deems advisable in connection with the administration of the Plan, and to construe, interpret, apply and enforce the Plan and any such rules and to remedy ambiguities, errors or omissions in the Plan;
(ii)    determine questions of eligibility and entitlement to benefits and any other terms of the Plan applicable to the Participants; the Committee’s determinations are conclusive and binding on all parties affected by its determinations;
(iii)    act under the Plan on a case-by-case basis; the Committee’s decisions under the Plan need not be uniform with respect to similarly situated Participants; and
(iv)    delegate its authority under the Plan to any director, officer, employee, or group of directors, officers and/or employees of the Company.
(b)    If any person with administrative authority becomes eligible or makes a claim for Plan benefits, that person will have no authority with respect to any matter specifically affecting his/her individual interest under the Plan, and the Committee will designate another person to exercise such authority.
(c)    Notwithstanding anything in the Plan to the contrary, after a Change in Control, neither the Committee nor the Board nor any other person or entity shall have discretionary authority in the administration of the Plan, and any court or tribunal that adjudicates any dispute, controversy or claim in connection with any severance benefits under this Plan will apply a de novo standard of 

1

review to any determinations made by the Committee or Board following such Change in Control.  Such de novo standard shall apply notwithstanding the grant of full discretion hereunder to the Committee, the Board, or any person or entity or characterization of any decision by the Committee, the Board, or by such person or entity as final, binding or conclusive on any party.
		
	4.
	Participation

Eligibility under the Plan is limited to Company employees designated by the Board as “executive officers” of WellCare within the meaning of Rule 3b-7 of the Exchange Act.  If the Board revokes such designation, the employee will cease being eligible for benefits under the Plan and cease being a Participant on the one year anniversary of such revocation; provided, however, that an employee who is a Participant immediately prior to a Change in Control shall continue being eligible for benefits under the Plan following a Change in Control subject to Section 9(a).  If a Participant is covered by any plan, program, policy or agreement with the Company that provides severance benefits upon termination of employment, then he or she will not be a Participant in this Plan.  To become a Participant, the employee must also become a party to a restrictive covenants agreement in the form provided by the Company.
		
	5.
	Severance Benefits

(a)    Before a Change in Control.  If a Participant’s employment with the Company is terminated after the Effective Date and before a Change in Control either (i) by the Company for reasons other than Cause, death, or Disability, or (ii) by the Participant for Good Reason, then the Participant shall receive: (x) payment of the Accrued Obligations, (y) the Cash Severance benefit described in this Section 5(a) based on the Participant’s title, and (z) Health Benefit Continuation described in this Section 5(a) based on the Participant’s title.
	
			
	Title as of Termination Date
	Cash Severance
	Health Benefit Continuation

	Chief Executive Officer
	1.5 x Base Salary plus
1.5 x Bonus
	18 months

	Executive Vice Presidents, Chief Financial Officer and General Counsel
	1 x Base Salary plus
1 x Bonus
	12 months

	Other Participants
	1 x Base Salary plus
1 x Bonus
	12 months

The Company shall pay the Base Salary portion of Participant’s Cash Severance as determined in accordance with this Section 5(a) in installments in accordance with the Company’s normal payroll schedule over 12 months beginning no later than the first regular payroll period following the expiration of any period during which a Participant may revoke the waiver and release of claims executed pursuant to Section 6(a), so long as that waiver and release is signed by the Participant and returned to the Company no later than 30 days after the Participant’s termination of employment and the Participant does not revoke such waiver and release of claims.  The Company shall pay the Bonus portion of Participant’s Cash Severance as determined in accordance with this Section 5(a) on the first anniversary of the Participant’s termination of employment, so long as the waiver and release has become effective and irrevocable as described above.  If a Change in Control occurs while payments of the Cash Severance as determined in accordance with this Section 5(a) are being made, the payments will continue to be paid as scheduled.

2

(b)    In Contemplation of a Change in Control.  If a Participant’s employment with the Company is terminated after the Effective Date and before a Change in Control by the Company for reasons other than Cause, death, or Disability, the Participant begins to receive severance in accordance with Section 5(a), a Change in Control occurs, and the Participant provides clear and convincing evidence to the Committee within 30 days after the Change in Control to support a claim that the Participant was terminated In Contemplation of a Change in Control, then within 70 days after the Change in Control, the Participant shall receive: (i) a single lump sum cash payment equal to the Cash Severance determined in accordance with Section 5(c) less the amount of Cash Severance already paid to the Participant under Section 5(a), and (ii) Health Benefit Continuation for the duration described in Section 5(c) based on the Participant’s title less the months of Health Benefit Continuation already provided under Section 5(a).  
(c)    After a Change in Control.  If a Participant’s employment with the Company is terminated within 24 months after a Change in Control either (i) by the Company for reasons other than Cause, death, or Disability, or (ii) by the Participant for Good Reason, then the Participant shall receive: (x) payment of the Accrued Obligations, (y) the Cash Severance benefit described in this Section 5(c) based on the Participant’s title as in effect on the date of the Change in Control, and (z) Health Benefit Continuation described in this Section 5(c) based on the Participant’s title as in effect on the date of the Change in Control.
	
			
	Title as of Termination Date
	Cash Severance
	Health Benefit Continuation

	Chief Executive Officer
	3 x Base Salary plus
3 x Bonus plus
1x Prorated Target Bonus
	18 moths

	Executive Vice Presidents, Chief Financial Officer and General Counsel
	2 x Base Salary plus
2 x Bonus plus
1x Prorated Target Bonus
	18 months

	Other Participants
	1.5 x Base Salary plus
1.5 x Bonus plus
1x Prorated Target Bonus
	18 months

The Company shall pay the Participant’s Cash Severance as determined in accordance with this Section 5(c) in a single lump sum cash payment no later than the first regular payroll period following the expiration of any period during which a Participant may revoke the waiver and release of claims executed pursuant to Section 6(a), so long as that waiver and release is signed by the Participant and returned to the Company no later than 30 days after the Participant’s termination of employment and the Participant does not revoke such waiver and release of claims.

(d)    Form of Severance under Existing Agreement.  Participants who are covered by an existing employment or severance agreement with the Company agree that their existing rights under that agreement are terminated and replaced with the provisions of this Plan; provided, however, that for the duration of the original remaining term of the employment or severance agreement only, the timing and form of severance (i.e., lump sum or installments) in the employment or severance agreement shall supersede the timing and form of payment provisions in this Section 5 and control the timing and form of payment of the Cash Severance.
(e)    Employment with Successor.  Notwithstanding anything to the contrary under the Plan, no severance benefits shall be paid to a Participant who is offered comparable employment by an entity that purchases a unit or asset of the Company or, following a Change in Control, by a successor to the Company.  “Comparable employment” is determined based on the facts and circumstances in 

3

each case, but means employment with duties, responsibilities, Base Salary, annual short-term incentive opportunity, annual long-term incentive opportunity and location that are substantially similar in the aggregate to the Participant’s prior employment with the Company.  A Participant who accepts comparable employment with a successor to the Company following a Change in Control remains entitled to receive severance benefits if the Participant’s employment is terminated as specified under Section 5(c).

(f)    Release of Claims and Restrictive Covenants.  Payment of Cash Severance and Health Benefit Continuation is subject to and contingent on the Participant’s satisfaction of the requirements of Section 6(a) (regarding waiver and release of claims) and Section 6(b) (regarding restrictive covenants).  If the period during which a Participant has discretion to execute or revoke the waiver and release of claims straddles two taxable years of the Participant, then the Company shall begin making the payment of Cash Severance in the second of such taxable years, regardless of which taxable year the Participant actually delivers the executed waiver and release to the Company.

(g)    Code Section 280G Cutback.  A Participant shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any payment received under the Plan, including, without limitation, any excise tax imposed by Code section 4999.  Notwithstanding anything to the contrary in the Plan, in the event that any payment or benefit received or to be received by a Participant pursuant to the terms of the Plan (the “Plan Payments”) or in connection with the Participant’s termination of employment or contingent upon a Change in Control pursuant to any plan or arrangement or other agreement with the Company (together with the Plan Payments, the “Payments”) would be subject to the excise tax imposed by Code section 4999, as determined by the Committee, then the Plan Payments shall be reduced to the extent necessary to prevent any portion of the Payments from becoming nondeductible by the Participant’s employer under Code section 280G or subject to the excise tax imposed under Code section 4999, but only if, by reason of that reduction, the net after-tax benefit received by the Participant exceeds the net after-tax benefit the Participant would receive if no reduction was made.  For this purpose, “net after-tax benefit” means (i) the total of all Payments that would constitute “excess parachute payments” within the meaning of Code section 280G, less (ii) the amount of all federal, state, and local income taxes payable with respect to the Payments calculated at the maximum marginal income tax rate for each year in which the Payments shall be paid to the Participant (based on the rate in effect for that year as set forth in the Code as in effect at the time of the first payment of the Payments), less (iii) the amount of excise taxes imposed on the Payments described in clause (i) above by Code section 4999.  If, pursuant to this Section, Payments are to be reduced, Payments will be reduced in this order: (1) Cash Severance, (2) Health Benefit Continuation, and (3) equity acceleration (to the extent applicable).

		
	6.
	Other Terms and Conditions of Eligibility

(a)    Waiver and Release of Claims.  As a condition to receiving severance benefits under the Plan, each Participant shall be required to sign and deliver to the Company, and may not revoke or violate the terms of, a general release of all claims against the Company, and the directors, officers, and employees of each of them, in the form attached as Exhibit A or such other form reasonably satisfactory to the Committee.  In no case will payments be made or begin before the end of any revocation period required by applicable law or regulation in connection with any release or waiver that the Participant is asked to sign.

4

(b)    Restrictive Covenants.  Any severance benefits specified under the Plan are provided, if at all, as consideration for, and are contingent upon, the Participant agreeing to, and abiding by, the restrictive covenants in the Participant’s restrictive covenants agreement with the Company.
(c)    At-Will Employment.  Each Participant is employed by the Company on an “at will” basis and nothing in this Plan shall give any Participant any right to continue in the employ of the Company.  A Participant shall have no rights under the Plan if the Participant’s employment is terminated by the Company, or any successor, with Cause or by the Participant without Good Reason, or due to the Participant’s death or Disability.
(d)    Nonduplication; No Impact on Benefits.
(i)    Payments to a Participant under the Plan shall be in lieu of any severance or similar payments that otherwise might be payable under any Company plan, program, policy or agreement with the Company that provides severance benefits upon termination of employment.
(ii)    Benefits payable under the Plan, whether paid in a lump sum or in periodic payments, will not increase or decrease the benefits otherwise available to a Participant under any company-sponsored retirement plan, welfare plan or any other employee benefit plan or program, unless otherwise expressly provided for in any particular plan or program.
(iii)    Any severance benefits specified under the Plan shall be reduced by the amount of any payment required by the Company to the Participant (A) because of insufficient advance notice of employment loss as may be required by law; or (B) under applicable law because of the termination of employment.
		
	7.
	Benefit Claims

(a)    Initial Claim.  Any claims concerning eligibility, participation, benefits or other aspects of the Plan must be submitted in writing and directed to the Committee, within 30 days after the communication of the determination that is the basis of the claim.  Within 30 days after receiving a claim, the Committee will (i) either accept or deny the claim completely or partially and (ii) notify the Participant of acceptance or denial of the claim.  If a claim is partially or wholly denied, the Committee will provide a written denial to the Participant no later than 30 days after receipt of the initial claim request.  The written denial shall include specific reasons for the denial, specific references to the Plan provisions upon which the denial was based, a description of any additional material or information necessary for the Participant to perfect the claim, an explanation of why such material is necessary, and instructions on the Plan’s claim review procedure.  If the Committee requires additional time to process a claim because of special circumstances, the Committee, in its sole discretion, may extend the period 30 additional days.  The Committee must notify the Participant of any such extension prior to the expiration of the 30‐day period commencing from the date the Committee first received written submission of the claim.
(b)    Appeals.  The Participant may request in writing to the Board a review of a denied claim within 30 days after receipt of such denial.  Such written request must contain an explanation as to why the Participant is seeking a review.  For purposes of the review, the Participant has the right to: (i) submit written comments, documents, records and other information relating to the claim for benefits; (ii) request, free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claim for benefits; and (iii) a review that takes into account all comments, documents, records, and other information the Participant submitted relating to the claim, 

5

regardless of whether the information was submitted or considered in the initial decision.  A decision on such review will be rendered in writing within 30 days of the Board’s receipt of a request for review, unless special circumstances require an extension of time for processing, in which case a decision will be rendered as soon as possible but no later than 60 days after receipt of the request for review provided that written notice is provided to the Participant or the Participant’s authorized representative before the extension commences.  A written notice affirming the denial of a claim will set forth the specific reasons for the decision and make specific reference to Plan provisions upon which the decision or appeal is based.  In preparation for filing such a request for review, the Participant or the Participant’s authorized representative may review pertinent plan documents, and as part of the written request for review, may submit issues and comments concerning the claim.  No claim may be brought before or submitted to a court of law or other governmental entity unless and until the claims process under this Section 7 has been exhausted.
		
	8.
	Recoupment

(a)    Right of Recoupment.  If, at any time, the Board or the Committee, as the case may be, in its sole discretion determines that any action or omission by the Participant constituted (i) wrongdoing that contributed to (A) any material misstatement in or omission from any report or statement filed by the Company with the U.S. Securities and Exchange Commission or (B) a statement, certification, cost report, claim for payment or other filing made under Medicare or Medicaid that was false, fraudulent or for an item or service not provided as claimed; (ii) intentional or gross misconduct; (iii) a breach of a fiduciary duty to the Company; (iv) fraud; (v) a violation of the restrictive covenants; or (vi) non-compliance with the Company’s Code of Conduct and Business Ethics (“Code of Conduct”), policies or procedures to the material detriment of the Company, then in each such case, the Participant’s participation in the Plan shall be immediately terminated and the Participant shall repay to the Company, upon notice to the Participant by the Company, up to 100% of the pre-tax amount paid to the Participant pursuant to this Plan.  The Board or the Committee, as the case may be, shall determine in its sole discretion the date of occurrence of such action or omission and the percentage of the pre-tax amount received pursuant to this Plan that must be repaid to the Company.
(b)    Method of Recoupment.  To the extent permitted by applicable law, the Company may enforce the recoupment of any or all amounts due under this Section 8 by withholding future payment of any severance benefits, seeking reimbursement of previously paid severance benefits, demanding direct cash payment, reducing any amount of compensation owed by the Company to the Participant, and/or such other means determined by the Board or Committee.
(c)    Nonexclusive Remedy.  The Company’s right of recoupment under this Section 8 is in addition to any remedy available to the Company with respect to any Participant, including, but not limited to, the initiation of civil or criminal proceedings and any right to repayment under the Sarbanes-Oxley Act of 2002, Dodd-Frank Wall Street Reform and Consumer Protection Act, and any other applicable law.
		
	9.
	General

(a)    Amendment and Termination of the Plan.  The Board or the Committee may amend or terminate the Plan in any respect; provided, however, if such amendment or termination (including any change to the severance benefits) shall be detrimental to a Participant, such amendment or termination shall be effective only with one year notice to such Participant; provided, further, that (i) any amendment or termination will not be effective if there is a Change in Control during the one 

6

year notice period, and (ii) the Plan cannot be amended or terminated during the 24 month period after a Change in Control.  A Participant ceasing to be eligible for a benefit under the Plan before a Change in Control, as described in Section 4, is not an amendment or termination of the Plan.
(b)    Funding.  Benefits payable under the Plan will be paid only from the general assets of the Company.  The Plan does not create any right to, or interest in, any specific assets of the Company.
(c)    No Mitigation.  The Participant shall not be obligated to seek other employment in mitigation of the amounts payable under any provision of the Plan, and the obtaining of such other employment shall not effect any reduction of the Company’s obligations to pay the severance benefits provided under the Plan (unless in violation of the restrictive covenants specified under Section 6(b)).
(d)    Withholding.  The Company may withhold from any payments made under the Plan all federal, state, local or other taxes required pursuant to any law or governmental regulation or ruling.
(e)    Right to Offset.  To the extent permitted by law, the Company may offset against any obligation to pay any portion of the severance benefit under the Plan any outstanding amount of whatever nature that the Participant then owes to the Company in the capacity as an employee.  However, no amount of “deferred compensation” (as defined under Treasury Regulation section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation sections 1.409A-1(b)(3) through (b)(12)) that is payable to a Participant under the Plan may be used to offset any amount that the Participant then owes to the Company.
(f)    Successors.  All rights under the Plan are personal to the Participant and without the prior written consent of the Committee shall not be assignable by the Participant.  The Plan shall inure to the benefit of and be enforceable by the Participant’s legal representative.  The Plan shall inure to the benefit of, and be binding upon, the Company and its successors and assigns.  Any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of WellCare shall be required to assume expressly and agree to perform the obligations set forth in the Plan in the same manner and to the same extent as the Company would be required to do so.
(g)    Governing Law.  The Plan and all determinations made and actions taken pursuant to the Plan shall be governed by the substantive laws, but not the choice of law rules, of the State of Delaware or by United States federal law.
(h)    Severability.  If any provision of the Plan is declared illegal, invalid or otherwise unenforceable by a court of competent jurisdiction, the provision shall be reformed, if possible, to the extent necessary to render it legal, valid and enforceable, or otherwise deleted, and the remainder of the terms of the Plan shall not be affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision.
(i)    Notices.  Notices and all other communications provided for under the Plan shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by United States certified mail, return receipt requested, or by overnight courier, postage prepaid, to the Company’s corporate headquarters address, to the attention of the Committee, or to the Participant at the home address most recently communicated by the Participant to the Company in writing.
(j)    409A Compliance.

7

(i)    The Plan is intended to comply with, or otherwise be exempt from, Code section 409A.  The preceding provision, however, shall not be construed as a guarantee by the Company of any particular tax effect to a Participant under the Plan.  The Company shall not be liable to a Participant for any payment made under the Plan, at the direction or with the consent of the Participant, which is determined to result in an additional tax, penalty or interest under Code section 409A, nor for reporting in good faith any payment made under the Plan as an amount includible in gross income under Code section 409A.
(ii)    “Termination of employment,” or words of similar import, as used in this Plan means, for purposes of any payments under this Plan that are payments of deferred compensation subject to Code section 409A, the Participant’s “separation from service” as defined in Code section 409A.  For purposes of Code section 409A, the right to a series of installment payments under this Plan shall be treated as a right to a series of separate payments.
(iii)    With respect to any reimbursement of expenses of, or any provision of in‐kind benefits to, a Participant, as specified under this Plan: (A) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Code section 105(b); (B) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (C) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.
(iv)    If a payment obligation under the Plan arises on account of a Participant’s termination of employment while a “specified employee” (as defined under Code section 409A and the regulations thereunder and determined in good faith by the Committee), any payment of “deferred compensation” (as defined under Treasury Regulation section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation sections 1.409A-1(b)(3) through (b)(12)) shall be made within 15 days after the end of the six-month period beginning on the date of such termination of employment or, if earlier, within 15 days after appointment of the personal representative or executor of the Participant’s estate following the death of the Participant.
		
	10.
	Definitions

The following definitions apply to the Plan:
“Accrued Obligations” means (i) the Participant’s Base Salary through the date of termination of employment, (ii) any accrued but unused paid time off and floating holiday pay, and (iii) unreimbursed business expenses.  The Company will pay the Accrued Obligations to the Participant in a single lump sum cash payment within 10 days after the Participant’s termination of employment with the Company.  
“Affiliate” means Comprehensive Health Management, Inc. and any other entity, whether now or hereafter existing, which controls, is controlled by, or is under common control with, WellCare (including, but not limited to, joint ventures, limited liability companies, and partnerships).
“Base Salary” means the annual rate of base salary in effect as of the date of termination of employment, determined without regard to any reduction thereof that constitutes Good Reason.
“Board” means the Board of Directors of WellCare.

8

“Bonus” means, (i) with respect to any Participant who has been employed by the Company for a period of time in which he or she participated in the two (2) most recently completed annual short-term incentive bonus cycles that ended before his or her date of termination of employment, the average of the two (2) annual short-term incentive bonuses, if any, paid by the Company to the Participant with respect to those annual short-term incentive bonus cycles, provided that, if the first annual short-term incentive bonus included in the calculation was pro rated to reflect the portion of the performance period in which the Participant was employed with the Company, then the amount of that first annual short-term incentive bonus shall be annualized solely for the calculation of the Bonus hereunder, or (ii) with respect to any Participant who has not been employed by the Company for a period of time in which he or she participated in the two (2) most recently completed annual short-term incentive bonus cycles that ended before his or her date of termination, the Participant’s annual short-term incentive bonus target amount in effect on the Participant’s date of termination of employment.     

“Cash Severance” means the sum of Base Salary, Bonus and, as applicable, Prorated Target Bonus as described in Section 5.

“Cause” means the occurrence of any one or more of the following events or conditions:

(i)    any willful act or willful omission, other than as a result of the Participant’s Disability, that constitutes a breach of any agreement to which the Company is a party or the Participant’s non-compliance with the Company’s Code of Conduct, policies or procedures to the material detriment of the Company;
(ii)     bad faith by the Participant in the performance of his duties, consisting of willful acts or willful omissions, other than as a result of the Participant’s Disability, to the material detriment of the Company;
(iii)    the Participant’s repeated failure to follow the reasonable and lawful directions of the Board (or committee of the Board) or Chief Executive Officer which is not cured within fifteen (15) days after written notice to the Participant; or
(iv)    the Participant’s commission of a crime that constitutes a felony involving fraud, conversion, misappropriation, or embezzlement under the laws of the United States or any political subdivision thereof.
It shall be a condition precedent to the Company’s right to terminate the Participant’s employment for Cause as defined in (i) or (ii) that (x) the Company shall have first given the Participant written notice stating with reasonable specificity the breach on which such termination is premised within ninety (90) days after the Company becomes aware of such breach, and (y) if such breach is susceptible of cure or remedy, such breach has not been cured or remedied within fifteen (15) days after the Participant’s receipt of such notice.

“Change in Control” means the effective date of the occurrence of any of the following events:

(i)    any Person or Group is or becomes the Beneficial Owner, directly or indirectly, of securities of WellCare representing more than 50% of either (A) the then fair market value of the then outstanding securities of WellCare or (B) the combined voting power of the then outstanding securities of WellCare;

9

(ii)    the direct or indirect sale or transfer by WellCare of all or substantially all of its assets in a single transaction or a series of related transactions;
(iii)    the merger, consolidation or reorganization of WellCare with or into another corporation or other entity, in which the shareholders of more than 50% of the voting power of WellCare’s voting securities immediately before such merger, consolidation or reorganization do not own more than 50% of the voting power of the voting securities of the surviving corporation or other entity immediately after such merger, consolidation or reorganization; or
(iv)    during any consecutive 12-month period, individuals who at the beginning of such period constitute the Board (together with any new directors whose election by the Board or nomination for election by the stockholders of WellCare was approved by a vote of a majority of the directors on the Board then still in office who were either directors at the beginning of such period or whose election or nomination for election was previously so approved) cease for any reason to constitute a majority of the members of the Board then in office.
Notwithstanding the terms of this Section, none of the foregoing events shall constitute a Change in Control if such event is not a “Change in Control Event” under Treasury regulation section 1.409A-3(i)(5) or successor guidance of the Internal Revenue Service.
For purposes of determining whether a Change in Control has occurred, a Person or Group shall not be deemed to be “unrelated” if: (A) such Person or Group directly or indirectly has Beneficial Ownership of more than 50% of the issued and outstanding voting power of WellCare’s voting securities immediately before the transaction in question, (B) WellCare has Beneficial Ownership of more than 50% of the voting power of the issued and outstanding voting securities of such Person or Group, or (C) more than 50% of the voting power of the issued and outstanding voting securities of such Person or Group are owned, directly or indirectly, by Beneficial Owners of more than 50% of the issued and outstanding voting power of WellCare voting securities immediately before the transaction in question.
The terms “Person,” “Group,” “Beneficial Owner,” and “Beneficial Ownership” shall have the meanings used in the Exchange Act.  Notwithstanding the foregoing, (A) Persons will not be considered to be acting as a “Group” solely because they purchase or own stock of WellCare at the same time, or as a result of purchases in the same public offering, (B) Persons will be considered to be acting as a “Group” if they are owners of a corporation that enters into a merger, consolidation, reorganization, purchase or acquisition of stock, or similar business transaction, with WellCare, and (C) if a Person, including an entity, owns stock both in WellCare and in a corporation that enters into a merger, consolidation, reorganization, purchase or acquisition of stock, or similar transaction, with WellCare, such Person shall be considered to be acting as a Group with other shareholders only with respect to the ownership in such corporation prior to the transaction.
“Code” means the Internal Revenue Code of 1986, as amended, and the regulations and Treasury guidance promulgated under it.
“Committee” means the Compensation Committee of the Board.  The Committee may delegate some or all of its authority under the Plan to any person, persons or subcommittee, in which event, the term “Committee” includes such person, persons or subcommittee to the extent of such delegation.
“Company” means WellCare and any Affiliate.

10

“Disability” means the Participant is unable to engage in any substantial gainful business activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or that has rendered the Participant unable effectively to carry out his/her duties and obligations to the Company or unable to participate effectively and actively in the management of the Company for a period of 90 consecutive days or for shorter periods aggregating to 120 days (whether or not consecutive) during any consecutive 12 months.
“Effective Date” has the meaning specified in Section 2.
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations and guidance promulgated under it.
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and guidance promulgated under it.
“Good Reason” means, without the Participant’s consent:
(i)    the occurrence of either of the following conditions which occurs prior to a Change in Control: (A) a material diminution in the Participant’s Base Salary, annual short-term incentive opportunity or annual long-term incentive opportunity, except as applicable generally to other similarly situated senior executives of the Company; or (B) the Company requiring the Participant to be based at any office or location outside of fifty miles from the Participant’s current employment location, except for travel reasonably required in the performance of the Participant’s responsibilities; or
(ii)    the occurrence of any of the following conditions which occurs following a Change in Control: (A) a material diminution in the Participant’s Base Salary, annual short-term incentive opportunity or annual long-term incentive opportunity; (B) the Company requiring the Participant to be based at any office or location outside of fifty miles from the Participant’s current employment location, except for travel reasonably required in the performance of the Participant’s responsibilities; or (C) a material diminution in the Participant’s authority, duties or responsibilities, provided, however, that with respect to Participants other than the Chief Executive Officer, Chief Financial Officer and General Counsel, the Participant shall not have Good Reason solely because the Participant’s duties and responsibilities are in respect of an entity that is not the most senior entity following the Change in Control.
It shall be a condition precedent to the Participant’s right to terminate Participant’s employment for Good Reason (before or after a Change in Control) that (A) the Participant shall have first given the Company written notice stating with reasonable specificity the breach on which such termination is premised within ninety (90) days after the Participant becomes aware or should have become aware of such breach, and (B) if such breach is susceptible of cure or remedy, such breach has not been cured or remedied within forty-five (45) days after receipt of such notice.
“Health Benefit Continuation” means subsidy by the Company of the portion of the Participant’s COBRA premium that exceeds the amount of the premium paid by active employees for the same coverage for the period following the Participant’s termination of employment with the Company designated in Section 5.  The Company will include the subsidy in the Participant’s taxable income and no gross-up will be provided.

11

“In Contemplation of a Change in Control” means the termination of the Participant’s employment by the Company for reasons other than Cause, death, or Disability within the 6 months prior to a Change in Control if the Participant demonstrates by clear and convincing evidence that the termination (i) was at the request of a third party who had taken steps reasonably calculated or intended to effect a Change in Control, or (ii) otherwise arose in contemplation or in anticipation of a Change in Control.
“Participant” means a person who has become a participant pursuant to Section 4 of the Plan.
“Plan” means this WellCare Health Plans, Inc. Executive Severance Plan.
“Prorated Target Bonus” means an amount equal to a pro rata portion of the Participant’s annual short-term incentive bonus target in effect on the Participant’s date of termination of employment based upon the percentage of the performance period that has elapsed through the date of termination of employment.

“WellCare” means WellCare Health Plans, Inc., a Delaware corporation.
Amended and Restated by the Board and the Compensation Committee: September 28, 2017

12Exhibit

Exhibit 4.2

FORESCOUT TECHNOLOGIES, INC. 
SPECIAL STOCKHOLDER VOTING AGREEMENT AND IRREVOCABLE PROXY
THIS SPECIAL STOCKHOLDER VOTING AGREEMENT AND IRREVOCABLE PROXY (this “Agreement”) is made as of September 13, 2017, by and among the Chief Executive Officer of ForeScout Technologies, Inc. (the “Company”) in office from time to time, who is currently Michael DeCesare (the “Representative”), Amadeus II ‘A’, Amadeus II ‘B’, Amadeus II ‘C’, Amadeus II ‘D’ GmbH & Co KG, Amadeus II Affiliates Fund LP, Amadeus IV Velocity Fund L.P., Amadeus EI L.P. and Amadeus EII L.P. (together, the “Amadeus Entities”) and the Company.  The Representative, the Amadeus Entities and the Company are each referred to herein as a “Party” and are collectively referred to herein as the “Parties.”
WHEREAS, as of the date hereof, the Amadeus Entities are the beneficial and record owners of such shares of capital stock of the Company as indicated on Schedule I hereto (the “Amadeus Shares”).
WHEREAS, for any matter (other than the Excluded Matters (as defined below)) requiring the vote or written consent of the stockholders of the Company pursuant to Sections 211 or 228 of the Delaware General Corporation Law (“DGCL”), the Amadeus Entities have agreed that as of the Effective Time (as defined below) the Amadeus Shares owned by the Amadeus Entities or any Affiliate (as defined below) of an Amadeus Entity as of the record date for such vote or written consent (collectively, the “Proxy Shares”) will be voted in identical proportions to the votes cast by other stockholders of the Company with respect to such matter. 
WHEREAS, the Amadeus Entities desire, as of the Effective Time, to appoint the Representative, with full power of substitution and re-substitution, as each Amadeus Entity’s proxy to represent and vote or written consent with respect to all of the Proxy Shares in accordance with the terms and provisions hereof. 
NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

SECTION 1
VOTING AGREEMENT AND IRREVOCABLE PROXY
1.1    Grant of Irrevocable Proxy.  Effective as of the effectiveness (the “Effective Time”) of the registration statement filed by the Company under the U.S. Securities Act of 1933, as amended, related to the first public offering of the Company’s capital stock in a bona fide, firm commitment underwritten offering (the “IPO”), each Amadeus Entity does hereby irrevocably (to the fullest extent permitted by law) appoint and constitute the Representative, as the sole and exclusive attorney-in-fact and proxy holder of such Amadeus Entity, with full power of substitution and re-substitution, to the full extent of such Amadeus Entity’s rights with respect to the voting of the Proxy Shares to exercise this proxy and to have exclusive power to vote or to act by written consent with respect to the Proxy Shares, or refrain from voting or acting by written consent with respect to the Proxy Shares, in identical proportions to the votes cast by other stockholders of the Company with respect to any matter (other than an Excluded Matter) at any meeting of the stockholders of the Company as contemplated by Section 211 of the DGCL, however validly called, and in connection with any action by written consent of the stockholders of the Company pursuant to Section 228 of the DGCL regarding such matter (to the extent the Company’s certificate of incorporation then in effect provides for the ability of stockholders to act by written consent). This proxy is irrevocable (to the fullest extent permitted by law), is coupled with an interest and, notwithstanding anything in Section 212(b) of the DGCL to the contrary, is of indefinite duration, unless and until this Agreement is terminated pursuant to Section 1.9.  For purposes of this Agreement, the term “Excluded Matter” shall mean (i) any matter relating to a Deemed Winding Up (as defined below) in the event that as of 

the record date of a vote at a meeting of stockholders or an action by written consent of the stockholders (to the extent the Company’s certificate of incorporation then in effect provides for the ability of stockholders to act by written consent), the Amadeus Entities own 18.0% or less of the Company’s then outstanding voting capital stock, (ii) any matter relating to the bankruptcy or insolvency of the Company, (iii) any matter that would adversely impact the rights, preferences or privileges of the Amadeus Entities in a manner different than the other stockholders of the Company (it being understood that the creation or issuance of securities with rights superior to, or pari passu with, the Amadeus Shares shall not be deemed an adverse effect with respect to such rights, preferences or privileges of the Amadeus Entities), (iv) any matter relating to Sections 1 (Registration Rights) or 11 (Miscellaneous) of the Amended and Restated Investor Rights Agreement by and among the Company, the Founders listed therein and the Investors listed therein, dated November 25, 2015 and as may be amended (the “IRA”), (v) any matter relating to the lock-up agreements or any other agreements that may be executed by an Amadeus Entity or any Affiliate of an Amadeus Entity in connection with the IPO, including but not limited to an underwriting agreement and custody agreement, if applicable, (vi) any amendment or waiver of this Agreement, or (vii) any matter that would limit or adversely affect the right or ability of the Amadeus Entities or any Affiliate of an Amadeus Entity to dispose of, or to direct the disposition of, any capital stock of the Company (including, without limitation, the Proxy Shares), including the right to tender, sell or exchange such shares in connection with a tender offer or other purchase or exchange offer commenced by the Company or any other person.   For the avoidance of doubt, in the event that as of the record date for a vote of the Company’s stockholders pursuant to the DGCL at any meeting of the stockholders of the Company as contemplated by Section 211 of the DGCL, however validly called, or any action by written consent of the stockholders of the Company pursuant to Section 228 of the DGCL (to the extent the Company’s certificate of incorporation then in effect provides for the ability of stockholders to act by written consent) with respect to which stockholders will vote or act by written consent regarding the approval of a Deemed Winding Up the Amadeus Entities own more than 18.0% of the Company’s then outstanding voting capital stock, the irrevocable proxy granted to the Representative pursuant to this Agreement shall continue to apply to the Amadeus Shares as to the approval of such Deemed Winding Up; provided, however, for the sake of clarity such agreement shall in no way limit or prohibit any rights of the Amadeus Entities to demand or exercise appraisal rights in accordance with the DGCL as to such Deemed Winding Up to the extent that such shares are not voted in favor of such Deemed Winding Up and appraisal rights are available in connection with such transaction.
Effective as of the Effective Time, each Amadeus Entity revokes any and all previous proxies with respect to the Proxy Shares solely to the extent such existing proxies conflict with the proxy granted in this Section 1.1 and shall not hereafter, unless and until this Agreement terminates or expires pursuant to Section 1.9, grant any other proxy or power of attorney with respect to any of the Proxy Shares, deposit any of the Proxy Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or understanding with any person to vote, grant any proxy or give instructions with respect to the voting of any of the Proxy Shares (including in each case with respect to any stockholder actions by written consent) which shall conflict with the proxy granted in this Section 1.1.
1.2    Affiliates.  Each Amadeus Entity shall cause each person or entity that it controls, is controlled by, or is under common control with (an “Affiliate”), to execute a joinder to this Agreement agreeing to be bound by all terms and conditions of this Agreement as an Amadeus Entity prior to any acquisition of shares of capital stock of the Company by such Affiliate.
1.3    Amadeus Director.  The Amadeus Entities shall instruct the Amadeus Director (as defined in the IRA) to execute an irrevocable resignation letter with the Company to resign as a director from the board of directors of the Company (the “Board”) immediately prior to and contingent upon the Effective Time.  In the event that the Amadeus Director fails to comply with such instructions, the Amadeus Entities shall take all 

-2-

necessary actions to remove the Amadeus Director from the Board immediately prior to and contingent upon the Effective Time and, notwithstanding the proportionality provisions of Section 1.1, in such event the Representative shall have the power to vote all of the Proxy Shares, at any meeting of the stockholders of the Company following the Effective Time held pursuant to Section 211 of the DGCL, however validly called, and in connection with any action by written consent of the stockholders of the Company pursuant to Section 228 of the DGCL, in favor of the removal of the Amadeus Director.
1.4    Termination of Amadeus Designee.  The Amadeus Entities acknowledge that pursuant to the terms of the IRA the Amadeus Entities’ right to designate a person to the Board pursuant to Section 7(a)(iii) of the IRA automatically terminates upon the earlier of (i) the consummation of an IPO of the Company and (ii) a Deemed Winding Up.  For the purposes of this Agreement, the term “Deemed Winding Up” shall mean a liquidation, dissolution or winding up of the Company, which shall be deemed to be occasioned by, or to include, but not be limited to, (i) any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, in which the stockholders of the Company immediately prior to such consolidation, merger or reorganization, own less than fifty percent (50%) of the voting power of the surviving entity immediately after such consolidation, merger or reorganization, provided that shares of the surviving or resulting corporation, or of the parent corporation of such surviving or resulting corporation, held by stockholders of the Company acquired by means other than the exchange or conversion of the shares of the Company in such consolidation, merger or reorganization shall not be used in determining if the shares of the Company outstanding immediately prior to such merger or consolidation continue to represent, or are converted or exchanged for shares which represent, immediately following such merger or consolidation the aforesaid majority but shall be used for determining the total outstanding voting power of the surviving or resulting entity; (ii) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Company; (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company; or (iv) the exclusive perpetual license of all or substantially all of the Company's intellectual property used in generating all or substantially all of the Company's revenue; provided, however, that a transaction shall not be deemed to be a liquidation, dissolution or winding up if its sole purpose is to change the state of the Company's incorporation.
1.5    Release and Waiver. To the fullest extent permitted by law, each Amadeus Entity hereby fully and forever releases, waives and relinquishes any right or entitlement it may have against the Representative and the Company and their respective officers, directors, employees, agents and assigns (“Releasees”) from any and all claims, liabilities or causes of action of any kind whatsoever, whether presently known or unknown, disclosed or undisclosed, suspected or unsuspected, including, without limitation, any claims, liabilities or causes of action premised upon any alleged breach of fiduciary duty or breach of any duty owed by an agent to its principal with respect to such action or inaction, arising from any acts or omissions that any Releasee may take or refrain from taking in the exercise of the proxy granted hereby and the voting of the Proxy Shares pursuant to the terms and conditions of this Agreement, except to the extent any such act or omission results from the willful misconduct or gross negligence of any Releasee.  Each Amadeus Entity acknowledges that it has been advised to confer with legal counsel, or has voluntarily waived such advice, and is familiar with the provisions of Section 1542 of the California Civil Code, which provides as follows: “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” Each Amadeus Entity, being aware of said code section, agrees to expressly waive any rights it may have thereunder, as well as under any other statute or common law principles of similar effect.

-3-

1.6    The Representative.  For the avoidance of doubt, this Agreement shall be deemed to bind any and all successive Chief Executive Officers of the Company, and such Chief Executive Officers of the Company shall possess the powers provided for herein, irrespective of whether any such Chief Executive Officer of the Company executes a joinder to this Agreement.  The Company shall indemnify and hold harmless the Amadeus Entities, their Affiliates and their respective officers, directors, employees, agents and assigns from and against any and all losses, liabilities, damages, claims, fees, penalties, taxes, interest, costs and expenses, including reasonable costs of investigation and defense and reasonable fees and expenses of counsel, experts and other professionals to the extent arising from the Representatives voting, or threatening to vote, the Amadeus Shares in breach of the terms and conditions of this Agreement.
1.7    Certain Stock Purchases.  Following the date on which the Amadeus Entities cease to own 10.0% of the outstanding shares of the Company’s voting capital stock, the Amadeus Entities agree not to purchase additional shares of capital stock of the Company without the Company’s prior written consent to the extent such purchase would cause the Amadeus Entities to own more than 10.0% of the outstanding shares of the Company’s voting capital stock.  For the avoidance of doubt, nothing in this Agreement shall in any manner limit or adversely affect the right or ability of the Amadeus Entities or their Affiliates to dispose of, or to direct the disposition of, any capital stock of the Company (including, without limitation, the Proxy Shares), including the right to tender, sell or exchange such shares in connection with a tender offer or other purchase or exchange offer commenced by the Company or any other person.
1.8    Costs and Expenses. The Amadeus Entities, the Company and the Representative shall each bear their own legal and other expenses with respect to this Agreement and the matters contemplated herein. 
1.9    Termination.  This Agreement shall terminate and be of no further force or effect upon the earliest of (i) consummation of a Deemed Winding Up, (ii) immediately following the date the Company’s independent registered public accounting firm as of the date of this Agreement (the “ForeScout Auditor”) ceases to serve as the Company’s independent auditor; provided that the Board’s audit committee has concluded that the Company’s newly appointed independent registered public accounting firm (the “New Audit Firm”) is independent from the Company under Rule 2-01 of SEC Regulation S-X (“Rule 2-01”) and the applicable rules of the Public Company Accounting Oversight Board (the “PCAOB”), even in the absence of this Agreement, and the New Audit Firm has concurred with such assessment, (iii) such date that the Amadeus Entities and their Affiliates in the aggregate cease to own in excess of 10.0% of the then-outstanding shares of common stock of GroupSystems Corporation (“Think Tank”) and the Amadeus Entities and their Affiliates cease to have the right to designate a director to Think Tank’s board of directors, (iv) such date that the Amadeus Entities and their Affiliates in the aggregate cease to own in excess of 10.0% of the then-outstanding shares of the Company’s voting capital stock, (v) after considering in good faith any input from the Amadeus Entities, including receipt of legal advice from a reputable source, the Board, in its sole discretion, concludes that the proxy and other matters provided for in this Agreement are no longer required, (vi) the date that the ForeScout Auditor’s business relationship with Think Tank is no longer in effect and is not being considered for renewal by ForeScout’s Auditor, (vii) following the Effective Time, such date that the Company ceases to be subject to the periodic reporting requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and does not otherwise file or furnish reports with the U.S. Securities and Exchange Commission or reasonably expect within the following twelve (12) months to be required to provide financial statements that must be audited in accordance with the rules of the SEC and PCAOB, (viii) upon the written consent of the Amadeus Entities, the Company and the Representative, (ix) ten (10) business days following the Effective Time, in the event that the IPO has not closed prior to such date; and (x) March 31, 2018, in the event the Effective Time has not occurred prior to such date; provided, however, that the provisions of (A) Section 1.7 shall remain in full force and effect and survive any termination of this Agreement pursuant to subsections (iii) or (iv) of this 

-4-

Section 1.9 and (B) Section 1.10 shall remain in full force and effect and survive any termination of this Agreement.
1.10    Further Agreement.  If following the termination of this Agreement for any reason, the Board’s audit committee or the ForeScout Auditor or the New Auditor, as applicable, determines that certain relationships between (i) any of the Amadeus Entities and/or their controlled entities, and (ii) the ForeScout Auditor or the New Auditor, as applicable, might impair such accounting firm’s independence from the Company, then, provided that the Company is then subject to, or reasonably expects to become subject to, the periodic reporting requirements of Sections 13(a) or 15(d) of the Exchange Act, or reasonably expects to be required to provide financial statements that must be audited in accordance with the rules of the SEC and PCAOB, the Parties shall negotiate in good faith to enter into a new agreement having substantially the same terms and conditions as this Agreement (provided that if such negotiation results from such aforementioned reasonable expectation, the effectiveness of such new agreement shall be conditioned on the Company actually becoming subject to such periodic reporting requirements or being required to provide such financial statements in accordance with the rules of the SEC and PCAOB).  
1.11    Severability.  In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed and interpreted in such manner as to be effective and valid under applicable laws.

SECTION 2
MISCELLANEOUS
2.1    Other Remedies; Specific Performance.  Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy.  The Parties hereto agree that irreparable damage would occur in the event that any provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.  Accordingly, it is agreed that the Parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions thereof as permitted by applicable laws, this being in addition to any other remedy to which they were entitled at law or equity.
2.2    Successors and Assigns.  The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the Amadeus Entities and the Company; provided, however, that an unaffiliated transferee or acquirer of shares of capital stock of the Company from the Amadeus Entities or their Affiliates shall not be bound by, or subject to, the terms or restrictions of this Agreement.
2.3    Governing Law.  This Agreement and all acts and transactions pursuant hereto and the rights of obligations of the Parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware without regard to its choice of laws principles.
2.4    Jurisdiction and Venue.  Any suit or proceeding relating to, arising out of or arising under this Agreement shall be brought in the federal or state courts located in the State of Delaware, which courts shall have the sole and exclusive in personam, subject matter and other jurisdiction in connection with such suit or proceedings and venue shall be appropriate for all purposes in such courts.

-5-

2.5    Counterparts.  This Agreement may be executed in any number of counterparts and signatures may be delivered by facsimile, each of which may be executed by less than all Parties, each of which shall be enforceable against the Parties actually executing such counterparts, and all of which together shall constitute one instrument.
2.6    Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
2.7    Notices.  All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the Party to be notified; (ii) when sent by confirmed facsimile or electronic transmission if sent during normal business hours of the recipient, if not, then on the next business day; (iii) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after deposit with an internationally recognized overnight courier, specifying next business day delivery, with written verification of receipt. All notices and other communications required or permitted hereunder shall be addressed to the respective Party at its address set forth on the signature page of this Agreement, or at such other address as the respective Party shall have furnished.  Subject to the limitations set forth in Section 232(e) of the DGCL, each of the Amadeus Entities consents to the delivery of any notice to stockholders given by the Company under the DGCL or the Company’s certificate of incorporation or bylaws by (i) facsimile telecommunication to the facsimile number set forth on the signature page of this Agreement (or to any other facsimile number for the Amadeus Entity in the Company’s records), (ii) electronic mail to the electronic mail address set forth on the signature page of this Agreement (or to any other electronic mail address for the Amadeus Entity in the Company’s records), (iii) posting on an electronic network together with separate notice to the Amadeus Entity of such specific posting or (iv) any other form of electronic transmission (as defined in the DGCL) directed to the Amadeus Entity. This consent may be revoked by an Amadeus Entity by written notice to the Company and may be deemed revoked in the circumstances specified in Section 232 of the DGCL.  “Business Day” shall mean a day other than Saturday, Sunday or any other day on which banks in either San Francisco, California or London, England are authorized or required to close.
2.8    Not a Voting Trust.  This Agreement is not a voting trust governed by Section 218 of the DGCL and should not be interpreted as such.
2.9    Amendment.  Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Amadeus Entities, the Company and the Representative. 
2.10    Jury Trial.  EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.   If the waiver of jury trial set forth in this section is not enforceable, then any claim or cause of action arising out of or relating to this Agreement shall be settled by judicial reference pursuant to California Code of Civil Procedure Section 638 et seq. before a referee sitting without a jury, such referee to be mutually acceptable to the parties or, if no agreement is reached, by a referee appointed by the Presiding Judge of the California Superior Court for Santa Clara County.  This paragraph shall not restrict a party from exercising remedies under the Uniform Commercial Code or from exercising pre-judgment remedies under applicable law.

-6-

2.11    Acknowledgement.  Each Party acknowledges that, in executing this Agreement, such Party has had the opportunity to seek the advice of independent legal counsel, and has read and understood all of the terms and provisions of this Agreement.  This Agreement shall not be construed against any Party by reason of the drafting or preparation hereof.
[SIGNATURE PAGE TO FOLLOW]

-7-

IN WITNESS WHEREOF, the Parties have executed this Voting Agreement and Irrevocable Proxy as of the date set forth above.

	
					
	AMADEUS II ‘A’

	 
	AMADEUS II ‘B’

	By:
	Amadeus Capital Partners Limited
its Manager

	 
	By:
	Amadeus Capital Partners Limited 
its Manager

	

Name:  
	/s/ Anne Glover
	 
	

Name:  
	/s/ Anne Glover

	

Title:
	Director
	 
	

Title:
	Director

	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	 
	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	 
	 
	 

	AMADEUS II ‘C’

	 
	AMADEUS II ‘D’ GMBH & CO KG

	By:
	Amadeus Capital Partners Limited
its Manager

	 
	By:
	Amadeus Capital Partners Limited 
its Manager

	

Name:  
	/s/ Anne Glover
	 
	

Name:  
	

/s/ Anne Glover

	

Title:
	                                                                             Director
	 
	

Title:
	Director

	Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	 
	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

IN WITNESS WHEREOF, the Parties have executed this Voting Agreement and Irrevocable Proxy as of the date set forth above.

	
					
	AMADEUS II AFFILIATES FUND LP

	 
	AMADEUS EI L.P.

	By:
	Amadeus Capital Partners Limited its Manager

	 
	By:
	Amadeus Capital Partners Limited its Manager 

	

Name:  
	/s/ Anne Glover
	 
	

Name:  
	/s/ Anne Glover

	

Title:
	 Director
	 
	

Title:
	Director

	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	 
	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	
					
	AMADEUS IV VELOCITY FUND L.P.

	 
	 
	AMADEUS EII L.P.

	By:
	Amadeus Capital Partners Limited 
its Manager 

	 
	By:
	Amadeus Capital Partners Limited 
its Manager 

	

Name:  
	/s/ Anne Glover
	 
	

Name:  
	/s/ Anne Glover

	

Title:
	Director
	 
	

Title:
	Director

	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

	 
	

Address: Suite 1, 2nd Floor, Quayside, Cambridge, England CB5 8AB

IN WITNESS WHEREOF, the Parties have executed this Voting Agreement and Irrevocable Proxy as of the date set forth above.

	
		
	FORESCOUT TECHNOLOGIES, INC.

	 
	 

	By:
	/s/ Darren Milliken

	Name: Darren Milliken

	Title: Senior Vice President and General Counsel

	 
	 

	Address:

	 
	 

	ForeScout Technologies, Inc.

	190 West Tasman Drive

	San Jose, CA USA 95134

	Darren.Milliken@forescout.com

IN WITNESS WHEREOF, the Parties have executed this Voting Agreement and Irrevocable Proxy as of the date set forth above.

	
		
	REPRESENTATIVE

	 
	 

	By:
	/s/ Michael DeCesare

	Name: Michael DeCesare

	Title: Chief Executive Officer

	 
	 

	Address:

	 
	 

	c/o ForeScout Technologies, Inc.

	190 West Tasman Drive

	San Jose, CA USA 95134

	Michael.DeCesare@forescout.com

Schedule I
Amadeus Shares

	
		
	Name
	Number of shares

	Amadeus II ‘A’
	4,214,168

	Amadeus II ‘B’
	2,809,443

	Amadeus II ‘C’
	1,966,643

	Amadeus II ‘D’ GmbH & Co KG
	93,623

	Amadeus II Affiliates Fund L.P.
	280,934

	Amadeus IV Velocity Fund L.P.
	1,144,889

	Amadeus EII L.P.
	1,297,185

	Amadeus EI L.P.
	421,645

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]